RARE

Ultragenyx Pharmaceutical Inc.

43.25 USD
-1.39 (-3.11%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Ultragenyx Pharmaceutical Inc. stock is up 5.57% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 72.73% of the previous 10 June’s closed higher than May. In the last 10 Unusual Options Trades, there were 5 CALLs, 5 PUTs. 86% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
15 Apr 13:49 17 May, 2024 50.00 CALL 197 34
15 Apr 14:32 19 Apr, 2024 50.00 PUT 158 242
15 Apr 17:32 17 Jan, 2025 50.00 PUT 45 3
15 Apr 17:39 17 Jan, 2025 50.00 PUT 35 3
15 Apr 18:21 17 Jan, 2025 50.00 PUT 35 3
14 May 16:33 15 Nov, 2024 50.00 CALL 650 0
17 May 14:57 19 Jul, 2024 45.00 CALL 171 492
21 May 16:45 19 Jul, 2024 35.00 PUT 588 6
07 Jun 14:27 19 Dec, 2025 40.00 CALL 40 0
10 Jun 16:51 15 Nov, 2024 55.00 CALL 500 0

About Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the. treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia.

  • Goldman Sachs
    Thu Jun 6, 09:02
    buy
    upgrade
  • Wedbush
    Fri May 31, 13:38
    hold
    confirm
  • Bank of America
    Fri May 31, 13:00
    buy
    confirm
  • Canaccord Genuity
    Fri May 31, 12:57
    buy
    confirm
  • Cantor Fitzgerald
    Fri May 31, 10:34
    buy
    confirm
  • Stifel
    Fri May 31, 09:27
    buy
    confirm
  • Baird
    Fri May 31, 08:14
    buy
    confirm